Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents

Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.

Abstract

We used a novel high-throughput drug screening assay, based on Luminex technology, to identify anti-myeloma agents capable of inhibiting cytokines and growth factors essential for multiple myeloma (MM) from a chemical library of 1120 compounds provided by MMRF. Tetracycline derivatives inhibited MM cell proliferation and osteoclast activating factors without obvious effect on cell viability. Steroid compounds specifically decreased angiogenesis-related factors, but stimulated osteoclast activating factors. Antihelmintic drugs potently inhibited cytokines and were cytotoxic. The screen identified potential candidates with potent anti-MM properties that need further investigation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / pharmacology
  • Anthelmintics / pharmacology
  • Anti-Infective Agents / pharmacology
  • Antineoplastic Agents / isolation & purification
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / metabolism
  • Bone Marrow Cells / cytology
  • Bone Marrow Cells / drug effects
  • Cardiac Glycosides / pharmacology
  • Cell Differentiation / drug effects
  • Cell Line, Tumor / drug effects
  • Cell Line, Tumor / metabolism
  • Cytokines / antagonists & inhibitors*
  • Cytokines / metabolism
  • Drug Screening Assays, Antitumor / methods*
  • Growth Inhibitors / isolation & purification
  • Growth Inhibitors / pharmacology*
  • High-Throughput Screening Assays / methods*
  • Humans
  • Immunoassay / methods*
  • Microspheres
  • Multiple Myeloma / drug therapy*
  • Osteoclasts / cytology

Substances

  • Adrenal Cortex Hormones
  • Anthelmintics
  • Anti-Infective Agents
  • Antineoplastic Agents
  • Cardiac Glycosides
  • Cytokines
  • Growth Inhibitors